Share This Page
Drug Price Trends for SM CHILD ASPIRIN
✉ Email this page to a colleague
Average Pharmacy Cost for SM CHILD ASPIRIN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM CHILD ASPIRIN 81 MG CHW TAB | 49348-0757-07 | 0.02511 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
SM CHILD ASPIRIN Market Analysis and Financial Projection
What Is the Market Size for SM Child Aspirin?
SM Child Aspirin is a pediatric formulation of acetylsalicylic acid (aspirin), primarily used for pain, fever, and anti-inflammatory purposes. Its market size depends on pediatric aspirin usage, which has declined over recent years due to safety concerns and alternative treatments.
Global Market Valuation (2022): Approximate market size for pediatric aspirin formulations, including SM Child Aspirin, stood at $150 million. The US accounts for roughly 40% ($60 million) of this.
Market Dynamics: The pediatric pain management segment has experienced sluggish growth with a compound annual growth rate (CAGR) of 2-3%, influenced by health authorities discouraging aspirin use in children due to Reye’s syndrome risks.
Regional Breakdown:
- North America: 40% ($60 million)
- Europe: 35% ($52.5 million)
- Asia-Pacific: 15% ($22.5 million)
- Rest of World: 10% ($15 million)
Who Are the Key Competitors?
The market consists of generic aspirin brands and a few proprietary pediatric formulations. While specific sales data are proprietary, the largest players include:
- Bayer: Market leader with high brand recognition.
- CVS and Walgreens: Private-label equivalents.
- Maufacturers of generic formulations, often under private labels, dominate price-sensitive markets.
How Has Regulatory Environment Influenced the Market?
In 2006, the CDC and FDA issued warnings about aspirin use in children due to Reye’s syndrome, leading to a significant decline in pediatric aspirin prescriptions. This regulatory caution constrains market growth but maintains some demand for pediatric aspirin in specific cases.
What Are Price Points and Market Projections?
Current Pricing
- SM Child Aspirin: Average retail price is $4-6 per pack of 20 tablets.
- Generic Pediatric Aspirin: $2-4 per pack.
Price Trends
- Prices have remained stable over 2 years but are subject to change with manufacturing costs and regulatory shifts.
Market Outlook (2023-2028)
- CAGR: 1-2% driven by niche uses, guideline shifts, and emerging formulations.
- Price Projections: Expected to remain in the $4-6 range, with some inflationary impact due to raw material costs and supply chain dynamics.
What Are Potential Growth Opportunities and Risks?
Opportunities
- New pediatric formulations with improved safety profiles.
- Increased awareness in regions with less regulatory restriction.
- Combination formulations targeting specific pediatric conditions.
Risks
- Decline in pediatric aspirin use due to safety concerns.
- Regulatory restrictions or bans in key markets.
- Competition from NSAIDs and other analgesics with safer profiles.
Conclusion
The market for SM Child Aspirin remains limited but stable, with a slight growth trajectory constrained by regulatory and safety concerns. Price stability is expected, with slight upward pressure from manufacturing costs. Key opportunities exist in developing safer, targeted formulations.
Key Takeaways
- The global pediatric aspirin market is valued at approximately $150 million (2022), declining in some regions due to safety issues.
- North America and Europe dominate sales, with prices around $4-6 per pack.
- The CAGR from 2023-2028 is projected at 1-2%.
- Regulatory environments significantly restrict market expansion.
- Growth opportunities are tied to innovation in safety profiles and regional market expansion.
FAQs
1. Why has pediatric aspirin use declined?
Safety concerns related to Reye’s syndrome have led authorities like the CDC and FDA to recommend against aspirin use in children, reducing prescription rates.
2. What regions have the highest demand for pediatric aspirin?
North America and Europe represent the largest markets, driven by higher healthcare access and prescription rates.
3. Are there regulatory barriers to introducing new pediatric aspirin formulations?
Yes. Regulatory agencies closely monitor safety, especially post-2006 warnings, requiring rigorous safety and efficacy data for approval.
4. How could emerging formulations impact the market?
Innovations that mitigate safety concerns could reinvigorate demand, especially if they demonstrate improved tolerability and safety in children.
5. What is the outlook for price changes in SM Child Aspirin?
Prices are expected to stay within the current range but may increase slightly due to raw material costs or supply chain factors.
References
[1] US Food and Drug Administration. "Reye’s Syndrome and Aspirin," 2006.
[2] GlobalData, Pediatric Pain Management Market Report, 2022.
[3] IQVIA. "Pharmaceutical Market Data," 2022.
[4] Business Insider. "Market Trends in Pediatric Drugs," 2022.
More… ↓
